Trusted Resources: People & Places
Online groups, photo galleries and blogs
Paul Orchard, MD
Healthcare Professional Director
Mucopolysaccharidosis (MPS) Center
University of Minnesota
660B Masonic Cancer Research Building
425 East River Parkway
Minneapolis, Minnesota, United States
Dr. Paul Orchard is the Medical Director of the Inherited Metabolic and Storage Disease Program and a Professor in the Department of Pediatrics, Division of Blood and Marrow Transplant & Cellular Therapy. Dr. Orchard’s focus is in the use of hematopoietic stem cell transplantation and other cell therapies for inherited metabolic disorders, with a special interest in the inherited Leukodystrophies, the Mucopolysaccharidoses and Osteopetrosis. His clinical research is in evolving new and combination therapies to decrease toxicity and improve outcomes, with a particular interest in the use of gene therapy approaches.
Dr. Paul Orchard completed his MD from Brown University Hospital, Residency in Pediatrics from University of Wisconsin Hospital, and Fellowship in Hematology-Oncology and Blood and Marrow Transplantation from the University of Minnesota Medical School. He serves as the Director of Mucopolysaccharidosis (MPS) Center, University of Minnesota.
Representative Publications:
Differences in MPS I and MPS II Disease Manifestations
Mucopolysaccharidosis Type I: Current Treatments, Limitations, and Prospects for Improvement
Treatment of Brain Disease in the Mucopolysaccharidoses
Unique Medical Issues in Adult Patients With Mucopolysaccharidoses
Related Content
-
AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for AVR-RD-05, a Gene Therapy for Mucopolysacc...AVROBIO, Inc., a leading clinical-stage ...
-
Maria Escolar, MD, MSDr. Escolar is board-certified in neurod...
-
Are You Considering Stem Cell Transplantation? Questions to Ask Your ProviderStem cell transplantation can be an over...
-
Julie Eisengart, PhD, LPDr. Julie Eisengart is an Associate Prof...
-
Denali Therapeutics Announces Continued Progress in DNL310 (ETV:IDS) Program for MPS II (Hunter Syndrome) Supporting...Denali Therapeutics Inc., a biopharmaceu...
-
Intracerebral Gene Therapy in Four Children With Sanfilippo B Syndrome: 5.5-Year Follow-Up ResultsWe report the safety (primary endpoint) ...
-
UPMC Children’s Hospital of Pittsburgh – Center for Rare Disease TherapyHurler syndrome (mucopolysaccharidosis t...